The FDA has given its final nod to W.L. Gore & Associates Inc. to market the Cardioform ASD occluder, aimed at correcting a congenital anomaly that causes a hole in the wall between the two upper chambers of the heart. The device, approved May 28, marks the newest addition to the Flagstaff, Ariz.-based health care and consumer products company's Cardioform occluder product line. The Cardioform ASD occluder is indicated for the percutaneous closure of ostium secundum atrial septal defects (ASDs). Read More
